1 |
Korea Food & Drug administration (2008): Guideline on Nonclinical Evaluation of Biopharmaceuticals, 11-147000 0-001713-14.
|
2 |
Korea Food & Drug administration (2008). Food & Drug statistical yearbook, 11-1470000-000023-10.
|
3 |
Meng, C., Lin, H., Huang, J., Wang, H., Cai, Q., Fang, L. and Guo, Y. (2009). Development of 5-valent conjugate pneumococcal protein A-capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb. Pathog., 47, 151-156.
DOI
ScienceOn
|
4 |
Pletz, M.W., Maus, U., Krug, N., Welte, T. and Lode, H. (2008). Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents., 32, 199-206.
DOI
ScienceOn
|
5 |
Rao, M. and Alving, C.R. (2000). Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv. Drug. Deliy. Rev., 41, 171-188.
DOI
ScienceOn
|
6 |
Richard, A.G., Thomas, J.K., Barbara, A.O. and Janis, K. (2003). Immunology (5th edition), W.H.Freeman, NewYork, pp. 335-336.
|
7 |
Ring, A., Weiser, J.N. and Tuomanen, E.I. (1998). Pneumococcal Trafficking across the Blood-Brain Barrier. Molecular Analysis of a Novel Bidirectional Pathway. J. Clin. Invest., 102, 347-360.
DOI
ScienceOn
|
8 |
Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R. and Edwards, K. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J., 19, 187-195.
DOI
ScienceOn
|
9 |
Charles, A.J., Paul, T., Mark, W. and Mark, S. (2005). ImmunoBiology-the immune system in health and disease (6th edition), Garland Science, NewYork, pp. 12-23.
|
10 |
Daoust, V., Carlo, D.J., Zelther, J.Y. and Perry, M.B. (1981). Specific Capsular polysaccharide of Type 45 Streptococcus pneumonia (American Type 72). Infect. Immun., 32, 1028-1033.
|
11 |
Henriksen-Lacey, M., Bramwell, V.W., Christensen, D., Agger, E.M., Andersen, P. and Perrie, Y. (2010). Liposome based on dimethyldioctadecylammonium promote a depot effect and enhance immungenicity of soluble antigen. J. Control. Release., 142, 180-186.
DOI
ScienceOn
|
12 |
Fenske, D.B., Chonn, A. and Cullis, P.R. (2008). Liposomal Nanomedicines: An Emerging Field. Toxicol. Pathol., 36, 21-29.
DOI
ScienceOn
|
13 |
Hausdorff, W.P., Feikin, D.R. and Klugman, K.P. (2005). Epidemiological differences among pneumococcal serotypes. Lancet. Infect. Dis., 5, 83-93.
DOI
ScienceOn
|